Skip to content

BridgeBio Pharma BBIO Return on equity

Discontinued — last reported Q4 '20

Return on equity at other companies

Pfizer logo
PfizerPFE
10.6%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-67.6%-20.3pp
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
9.1%+2.8pp
ALN
Alnylam PharmaceuticalsALNY
66.9%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-76.7%-923pp
Roivant Sciences logo
Roivant SciencesROIV
-17.1%-17.7pp

Other financials

Income statement

See full
Revenue$194.5M+66.8%
Gross profit$184.6M+61.9%
Operating income-$106.0M-1.5%
Net income-$166.6M+1.8%
EPS (diluted)-$0.84+4.5%

Balance sheet

See full
Cash & equivalents$882.0M+62.5%
Total debt$3.3B+32,101%
Total equity-$2.3B-38.2%
Total assets$1.4B+55.5%

Cash flow

See full
Operating cash flow-$197.3M+1.0%
CapEx$69.0K
Free cash flow-$197.3M+0.9%

Valuation

See full
Market cap$12.98B+119%
Enterprise value$15.36B+178%
P/S22.4×-24.1×

Profitability

See full
Gross margin95.1%-0.2pp
Operating margin-90.5%-41.2pp
Net margin-125.9%-54.5pp
FCF margin-76.8%

Returns & leverage

See full
Debt / equity
Current ratio1.5×-3.0×

Where this comes from

Calculated from BridgeBio Pharma’s reported figures.

Based on trailing twelve months.

The official record: BridgeBio Pharma’s 10-K, filed February 23, 2023, on SEC EDGAR. View the filing →

Questions, answered.

What does return on equity mean?
How much profit the company earns on the money shareholders have invested.
How do you interpret return on equity?
Higher is better, but very high ROE can be manufactured by leverage — a thin equity base inflates the ratio. Read it next to debt-to-equity and ROIC to tell genuine returns from balance-sheet engineering.
How does return on equity compare across companies?
Comparable across peers, with the leverage caveat. Negative or near-zero equity makes ROE meaningless, so it is suppressed there.